ASLAN Pharmaceuticals Limited
ASLN · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $18 | $21 | $41 | $41 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $12 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $2 | $3 | $3 | $2 |
| Total Curr. Assets | $21 | $24 | $44 | $55 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | -$0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $0 | $0 | $0 | $0 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $21 | $25 | $45 | $55 |
| Liabilities | – | – | – | – |
| Payables | $10 | $8 | $4 | $6 |
| Short-Term Debt | $7 | $2 | $14 | $13 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $2 | $0 | $2 | $2 |
| Other Curr. Liab. | $0 | $3 | $0 | $2 |
| Total Curr. Liab. | $20 | $13 | $21 | $24 |
| LT Debt | $19 | $25 | $25 | $24 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $19 | $25 | $25 | $24 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $39 | $38 | $46 | $49 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $65 | $64 | $64 | $64 |
| Retained Earnings | -$331 | -$321 | -$309 | -$299 |
| AOCI | $0 | $24 | -$0 | -$0 |
| Other Equity | $248 | $220 | $245 | $242 |
| Total Equity | -$18 | -$13 | -$1 | $6 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $21 | $25 | $45 | $55 |
| Net Debt | $8 | $6 | -$2 | -$3 |